Sun Pharmaceutical Industries and Aurobindo Pharma are recalling products from the US market due to manufacturing issues. Sun Pharma's subs...

Consolidated net profit is seen declining 1.4% YoY to Rs 2,033 crore. India’s largest pharmaceutical company by market capitalization is sc...

DED is caused when the quantity or quality of tears fails to keep the surface of the eye properly lubricated, and associated with symptoms ...

Sun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 254653.42 Crore) opera...

Sun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 213972.69 Crore) opera...

Sun Pharma performance has been a mixed bag in the near term as the shares dropped 13 per cent in the last month, whereas rose close to 7 p...

The product is the first dry eye treatment available in Canada that is delivered with nanomicellar (NCELL) technology, which improves the b...

CLSA, which raised the target price on Sun Pharma the most, said the drug maker's results were above estimates with key geographies perform...

Analysts have cut their price targets marginally following the hit on bottom line.

The drug maker had reported a loss of Rs 269.60 crore in the corresponding quarter last year.

Buy Sun Pharmaceutical Industries Ltd. at a price target of Rs 540.0 .

One of the company's wholly-owned subsidiaries has commercialised Cequa 0.09 per cent in the US, Sun Pharma said in a filing to BSE.

Sun Pharma is a largecap company, operating in pharmaceuticals and health care sector.

Buy Sun Pharmaceutical Industries at a price target of Rs 581.

The company had reported Rs 321.57 crore profit in the same quarter last year.

New Delhi, Aug 16 () Sun Pharma has received approval from the US health regulator for CEQUA (cyclosporine ophthalmic solution), used to in...

The drug in question is CEQUA (cyclosporine ophthalmic solution) 0.09 per cent.